Abstract:New understandings about RAG1 and RAG2 gene expression have recently been gained. Rag expression molecular pathways are now known to support research on genetic variants that influence regulatory domains for lymphoid development. The RAG1/RAG2 complex might serve as a model for RAG alterations in vivo and in vitro recombination experiments. These data indicate the approximate relationship between RAG deficiency genotype and phenotype. Although this concept has not yet been proven, it is theorized that hypomorphic RAG mutations restrict RAG complexes and interfere with appropriate T-and B-cell development.A unique cellular and animal model has uncovered significant immunological and clinical insights regarding RAG mutations. Rag mutations causing below-normal levels of T and B cell development have considerable ramifications on thymic lymphostromal cross talk as well as on receptor editing in the bone marrow and on the survival of self-reactive peripheral B cells. These difficulties account for the higher occurrence of autoimmune symptoms in people and animals with hypomorphic RAG mutations. A study looking at human T cell development used the in vitro methodology to investigate RAG-mutant mice. Finally, emerging therapy options may help patients with RAG deficiency, especially those with severe immune dysregulation. Useful therapy could benefit other people with immune inborn errors as well.New exploratory approaches are emerging to help cure RAG deficiency. These techniques have offered a distinct understanding of RAG deficiencies employing artificial thymic organoids (ATOs) and induced pluripotent stem cells, respectively (iPSCs). novel possible therapeutic approaches, such as lentiviral vector‐mediated gene therapy, gene editing, and nongenotoxic conditioning regimens for hematopoietic stem cell transplantation (HSCT).

RAG-1-deficient mice have no mature B and T lymphocytes

RAG gene and B cell lymphoma

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

Noncore RAG1 regions promote Vβ rearrangements and αβ T cell development by overcoming inherent inefficiency of Vβ recombination signal sequences

The RAG1 N-terminal region regulates the efficiency and pathways of synapsis for V(D)J recombination

The R229Q mutation of Rag2 does not characterize severe immunodeficiency in mice

Disruption of the RAG2 zinc finger motif impairs protein stability and causes immunodeficiency

RAG2 Abolishes RAG1 Aggregation to Facilitate V(D)J Recombination.

RAG suppresses group 2 innate lymphoid cells

Contribution of Rag1 to Spatial Memory Ability in Rats

RAG1 splicing mutation causes enhanced B cell differentiation and autoantibody production

The RAG cell line defines a new complementation group of MHC class II deficiency

RAG deficiencies: Recent advances in disease pathogenesis and novel therapeutic approaches

Restoration of T and B Cell Differentiation after RAG1 Gene Transfer in Human RAG1 Defective Hematopoietic Stem Cells

Emerging therapy options may help patients with RAG deficiency, especially those with severe immune dysregulation

Nucleolar localization of RAG1 modulates V(D)J recombination activity

RAG1/2 induces double‐stranded DNA breaks at non‐Ig loci in the proximity of single sequence repeats in developing B cells

RAG1 and RAG2 non-core regions are implicated in leukemogenesis and off-target V(D)J recombination in BCR-ABL1-driven B-cell lineage lymphoblastic leukemia

Cloning and characterization of the human recombination activating gene 1 (RAG1) and RAG2 promoter regions.

Generation of Recombination Activating Gene-1-Deficient Neonatal Piglets: A Model of T and B Cell Deficient Severe Combined Immune Deficiency

Collaboration of RAG2 with RAG1-like proteins during the evolution of V(D)J recombination